אולנזאפין דקסל 5 מ"ג

Nazione: Israele

Lingua: ebraico

Fonte: Ministry of Health

Principio attivo:

OLANZAPINE 5 MG

Commercializzato da:

DEXCEL PHARMA TECHNOLOGIES LTD

Codice ATC:

N05AH03

Forma farmaceutica:

TABLETS

Via di somministrazione:

PER OS

Prodotto da:

DEXCEL LTD

Gruppo terapeutico:

OLANZAPINE

Indicazioni terapeutiche:

Acute and maintenance treatment of schizophrenia. Olanzapine is indicated for the management of the manifestations of psychotic disorders. Olanzapine is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder: the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.

Data dell'autorizzazione:

2012-05-01